Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice

被引：0
|
作者：
Jadvar, Hossein [1 ,2 ]
Iravani, Amir [3 ]
Bodei, Lisa [4 ]
Calais, Jeremie [5 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Div Nucl Med, Los Angeles, CA 90007 USA
[2] Univ Southern Calif, Mol Imaging Ctr, Keck Sch Med, Dept Radiol, Los Angeles, CA 90007 USA
[3] Univ Washington, Dept Radiol, Div Nucl Med, Seattle, WA USA
[4] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY USA
[5] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷 / 12期
关键词：
RESISTANT PROSTATE-CANCER; PROGRESSION-FREE SURVIVAL; PSMA PET/CT; 177LU-PSMA-617; MULTICENTER; SAFETY;
D O I：
10.2967/jnumed.124.268023
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：1851 / 1854
页数：4
相关论文
共 50 条
  • [1] A Hangover Under 177Lu-PSMA-617 Therapy
    Poterszman, Nathan
    Somme, Laura
    Bund, Caroline
    Hutt, Emilie
    Somme, Francois
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) : 582 - 583
  • [2] Radiation Dosimetry in 177Lu-PSMA-617 Therapy
    Jackson, Price
    Hofman, Michael
    McIntosh, Lachlan
    Buteau, James Patrick
    Kumar, Aravind Ravi
    SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (02) : 243 - 254
  • [3] 177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy
    Clements, Sarah
    Tempesta, Daniel
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2022, 50 (03) : 213 - 214
  • [4] 177Lu-PSMA-617: Brazilian Experience
    Villas Boas, Cristian Wieczorek
    Silva, Jefferson de Jesus
    Benedetto, Raquel
    Mengatti, Jair
    De Araujo, Elaine Bortoleti
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [5] Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy
    Mair, Christian
    Warwitz, Boris
    Fink, Katharina
    Scarpa, Lorenza
    Nilica, Bernhard
    Maffey-Steffan, Johanna
    Buxbaum, Sabine
    Virgolini, Irene J.
    ANNALS OF NUCLEAR MEDICINE, 2018, 32 (07) : 499 - 502
  • [6] Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy
    Christian Mair
    Boris Warwitz
    Katharina Fink
    Lorenza Scarpa
    Bernhard Nilica
    Johanna Maffey-Steffan
    Sabine Buxbaum
    Irene J. Virgolini
    Annals of Nuclear Medicine, 2018, 32 : 499 - 502
  • [7] Production and radiochemical purity of 177Lu-PSMA-617 for clinical trial
    Asad, Ali
    Scharli, Rainer
    Morandeau, Laurence
    Price, Roger
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S527 - S527
  • [8] Administration of 177Lu-PSMA-617 as Compared to 177Lu-Dotatate
    Patel, P.
    McCall, K.
    MEDICAL PHYSICS, 2022, 49 (06) : E811 - E812
  • [9] Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges
    Ravi, Praful
    Whelpley, Bridget
    Kelly, Emma
    Wolanski, Andrew
    Ritzer, Jolivette
    Robertson, Matthew
    Shah, Hina
    Morgans, Alicia K.
    Wei, Xiao X.
    Sunkara, Rajitha
    Pomerantz, Mark
    Taplin, Mary -Ellen
    Kilbridge, Kerry L.
    Choudhury, Atish D.
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (03) : 349 - 350
  • [10] Dose Escalation Experience with 177Lu-PSMA-617
    Rathke, H.
    Giesel, F. L.
    Flechsig, P.
    Kopka, K.
    Mier, W.
    Hohenfellner, M.
    Haberkorn, U.
    Kratochwil, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S280 - S281
12345